CD3-targeting switchable car-t cells of which CD3 gene is edited

Switchable CAR-T cells with reduced CD3 expression and an adapter molecule for regulated activity address the fratricide and immunodeficiency issues in CAR-T cell therapies, enabling effective and safe targeting of T cell-derived tumors.

WO2024241208A1PCT designated stage expired Publication Date: 2024-11-28SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2024/054913
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-19
Filing Date
2024-05-20
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current CAR-T cell therapies targeting CD3 antigens face challenges such as fratricide, where CAR-T cells attack normal T cells, leading to immunodeficiency and limited efficacy against T cell-derived tumors like peripheral T cell lymphoma, due to CD3 expression in both tumor cells and normal T cells.

Method used

Development of CD3-targeting switchable CAR-T cells with reduced or eliminated CD3 expression, utilizing an adapter molecule that regulates CAR-T cell activity, allowing specific binding to tumor cells only during killing and preventing binding after the function is completed, thereby minimizing toxicity to normal T cells.

Benefits of technology

This approach effectively prevents fratricide and immunodeficiency toxicity, enhancing the therapeutic index of CAR-T cell therapy by ensuring selective tumor targeting while maintaining normal T cell function, thus improving treatment outcomes for T cell-derived tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IB2024054913_28112024_PF_FP_ABST
    Figure IB2024054913_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to: CD3-targeting switchable CAR-T cells (chimeric antigen receptor T cells) of which a CD3 gene is edited; and use thereof for treating T cell-derived tumors. By using CAR-T cells with reduced or eliminated expression of CD3 and an adapter molecule that regulates the activity of the CAR-T cells in combination, the CAR-T cells exhibit anti-fratricide ability and the ability to avoid immunodeficiency toxicity, and thus can be effectively used in a therapeutic agent for T cell-derived tumors.
Need to check novelty before this filing date? Find Prior Art

Description

[0001]

specification

[0002]

Title of invention

[0003] CD3 gene-edited CD3-targeting switchable CAR-T cells {CD3 targeting switchable CAR-T cells whose CD3 genes are edited}

[0004]

Technical Field

[0005]

Invention Technology

[0006] Although CD3, which is widely expressed in T-cell lymphoma, is the ideal target antigen for CARs, it has the disadvantage of being expressed in normal T cells as well. Therefore, when manufacturing T cells transfected with a CD3-targeting CAR gene, there is a technical barrier in that CAR-T cells cannot be manufactured because they attack the CAR-T cells themselves and induce cell suicide (fratricide). In addition, another technical barrier to CD3-targeting CAR-T cells is that when these cells are introduced into a patient's body, they may kill not only T-cell lymphoma but also the patient's normal T cells, causing immunodeficiency side effects in the patient. Therefore, the present invention has overcome the two technical difficulties by producing a conjunctive CD3-targeting CAR-T cell that performs CD3-targeting function only during tumor killing and does not bind to CD3 after the killing function is completed, thereby completing the invention of a CAR-T cell treatment for peripheral T-cell lymphoma.

[0007]

Prior Art Documents

[0008]

Patent Document

[0009] (Patent Document 0001) Korean Patent Publication No. 2018-0031727 (Published: March 28, 2018)

[0010]

Detailed Description of the Invention

[0011]

Technical Problem

[0012]

Technical Solution

[0013] In CAR T cell therapy, after CAR T cells injected into a subject's body are used to selectively kill tumors, and after the tumor is effectively reduced, the remaining residual CAR T cells exhibit side effects of killing normal cells. This is called CAR T immunodeficiency toxicity or normal T cell toxicity. The adapter molecule showed the effect of CAR T cell immunodeficiency toxicity or normal T cell toxicity evasion ability by regulating the activation of chimeric antigen receptor T cells. In one embodiment of the present invention, unlike existing CAR T cells that directly target existing tumors, the CAR T cell of the present invention binds to the adapter molecule itself and binds to the tumor cell targeted by the adapter molecule, so that even when the CAR T cell is injected in the absence of the adapter molecule, no toxicity is exhibited toward the target cell or tumor. In other words, CAR T cells are activated only in the presence of the adapter molecule, and thus exhibit toxicity toward the target cell or tumor. Therefore, the adapter molecule can induce the activation or inactivation of CAR T cells. For this reason, the adapter molecule is also called a switchable molecule. Accordingly, the use of the adapter molecule to induce activation of chimeric antigen receptor T cells includes the use of the ability to prevent immunodeficiency by alleviating cytotoxicity and normal T cell killing side effects of residual CAR T cells after CAR T cell therapy. Another aspect of the present invention provides a chimeric antigen receptor T cell (CAR-T cell) in which CD3 expression is reduced or eliminated, wherein the CAR-T cell expresses a chimeric antigen receptor comprising (i) an extracellular domain comprising an antibody or an antigen-binding fragment thereof that specifically binds to a second moiety of the adapter molecule, (ii) a transmembrane domain, and (iii) an intracellular signaling domain. The "first moiety",The "second moiety" or "adapter molecule" is as described above. As used herein, the term "extracellular domain" refers to a domain that protrudes outside the cell and binds to a ligand, etc. As used herein, the term "intracellular domain" refers to a domain that is located inside the cell membrane of a cell, i.e., in the cytoplasm, and transmits a signal transmitted by binding between the extracellular domain and a ligand into the cell. In one specific example, the chimeric antigen receptor (hereinafter also referred to as "CAR") refers to a protein that fuses the cell membrane or intracellular signaling site of a T-cell activation protein (CD3-zeta chain, CD28, 41BBL, 0x40, I COS, high-affinity receptor for IgE (FCERI) and other T-cell activation proteins) with an antigen-binding site (single chain Fv fragment) of a cancer antigen-specific antibody. Specifically, the first-generation CAR includes an extracellular domain including an antigen recognition site specifically expressed in cancer cells, a transmembrane domain, and an intracellular signaling domain, and may use only CD3 as the signaling domain. The second-generation CAR has a structure that combines a costimulatory domain (CD28 or CD137 / 4-1BB) and CD3 to improve responsiveness to immune cells, and may increase the number of CAR-containing immune cells remaining in the body compared to the first-generation CAR. The third-generation CAR may have a structure that combines a costimulatory domain with 4-1BB, CD28, or 0X40, etc., using two or more costimulatory domains to achieve expansion and persistence of immune cells including the CAR in the body. The fourth generation CARs include additional genes encoding cytokines such as IL-12 or IL-15, allowing for additional expression of cytokine-based CAR immunoproteins, while the fifth generation CARs include interleukin receptor chains, to enhance immune cells.For example, it may additionally include IL-2RP. In one specific example, the chimeric antigen receptor may have a structure of a first-generation CAR to a fifth-generation CAR. In one specific example, the extracellular connection portion of the chimeric antigen receptor may further include a hinge domain. In one specific example, the hinge domain may be characterized by being composed of an oligopeptide or a polypeptide and comprising 1 to 100 amino acid residues, specifically, 10 to 70 amino acid residues, but is not limited thereto. In one specific example, the intracellular signaling domain of the chimeric antigen receptor is a portion located inside the cell membrane of an immune cell, i.e., in the cytoplasm, and may refer to a portion that transmits a signal into the cell when the antigen binding domain included in the extracellular domain binds to a target antigen and activates an immune response of the immune cell. In one specific embodiment, the intracellular signaling domain may be, but is not limited to, one or more intracellular signaling domains selected from the group consisting of CD3 zeta (《), CD3 gamma (Y), CD3 delta (6), CD3 epsilon (E), FcR gamma, FcR beta, CD5, CD22, CD79a, CD79b, and CD66d, and in one embodiment, the intracellular signaling domain of the chimeric antigen receptor is CD3 zeta (《). In one specific embodiment, the intracellular signaling domain may be characterized by further comprising, but is not limited to, a costimulatory domain. The co-stimulatory domain according to the present invention is CD2, CD7, CD27, CD28, CD30, CD40, 4-lBB(CD137), 0X40(CD134), I COS, LFA-1, GITR, MyD88, DAP1, PD-1, LIGHT, NKG2C,B7-H3 and CD83, and may include one or more costimulatory domains selected from the group consisting of ligands that specifically bind thereto, but is not limited thereto. In one specific embodiment, the chimeric antigen receptor may be characterized by comprising one or more intracellular signaling domains and one or more costimulatory domains. In one specific embodiment, the costimulatory domain may be 4-1BB. The reduction or elimination of CD3 expression of the chimeric antigen receptor T cell may be achieved by removing CD3, specifically endogenous CD3, of the T cell or CAR-T cell introduced with the CAR gene before introducing the CAR gene, or by removing the TCR. That is, the reduction or elimination of CD3 expression may be achieved by directly removing the CD3 gene or indirectly reducing, suppressing, or eliminating the expression of CD3 by removing the TCR. Reducing or eliminating the expression of the CD3 or TCR may be performed by a genome editing technique including a CRISPR system, specifically, CRISPR / Cas9, TALEN, Zinc fi nger nuclease, base-editing and primer-editing, or by a nucleic acid selected from the group consisting of antisense RNA, antagomir RNA, si RNA, shRNA and miRNA. The CAR T cell may be one that binds to the second moiety of the adapter molecule. More specifically, the CAR T cell may exhibit cytotoxicity against a target cell or a tumor cell by binding to the second moiety of the adapter molecule. That is, the CAR T cell, more specifically, the extracellular domain of the CAR T cell may include an antibody or an antigen-binding fragment thereof having binding ability to the second moiety of the adapter molecule. The second moiety may be a His tag. Therefore,The CAR T cell, more specifically, the extracellular domain of the CAR T cell, may include a protein having a specific binding ability to a His tag, specifically, an antibody or an antigen-binding fragment thereof. In one embodiment of the present invention, the antibody or antigen-binding fragment thereof that specifically binds to the His tag may include an amino acid sequence of SEQ ID NO: 63, a part thereof, or an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identity therewith. Even if the present application describes "comprising a gene sequence / amino acid sequence of a specific sequence number" or "having a gene sequence / amino acid sequence of a specific sequence number," it is obvious that a gene sequence / amino acid sequence in which a part of the sequence is deleted, modified, substituted, or added may also be used in the present application, as long as it has the same or corresponding function as that composed of the gene sequence / amino acid sequence of the corresponding sequence number. In addition, in the present application, the gene sequence and the base sequence may be used interchangeably. For example, if it has the same or corresponding function as the CAR T cell, it is obvious that it is within the scope of the present application that a meaningless sequence is added to the sequence or the end of the sequence number, or a part of the sequence is deleted from the sequence or the end of the sequence number. Homology and identity refer to the degree of relationship between two given base sequences and can be expressed as a percentage. The terms homology and identity are often used interchangeably. Whether any two sequences have homology or identity can be determined using a known computer algorithm such as the "FASTA" program using default parameters, for example, as in Pearson et al (1988) [Proc. Natl. Acad. Sci. USA 85]: 2444. Or,The Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needleman program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277) (version 5.0.0 or later) can be determined using the GCG program package (Devereux, J., et al., Nucleic Acids Research 12: 387 (1984)), BLASTP, BLASTN, FASTA (Atschul, [S.] [F.,] [ET AL, J MOLEC BIOL 215]: 403 (1990): Guide to Huge Computers, Martin J. Bishop, [ED.,] Academic Press, San Diego, 1994, and [CARILLO ETA / .] (1988) SIAM J Applied Math 48: 1073). For example, sequence homology or identity can be determined using BLAST or ClustalW of the National Center for Biotechnology Information Database in the United States. Another aspect of the present invention provides a complex comprising a chimeric antigen receptor T cell in which the expression of CD3 is reduced or eliminated and an adapter molecule that regulates the activity of the CAR-T cell. Another aspect of the present invention provides a kit for preventing or treating a T cell-derived tumor, comprising a chimeric antigen receptor T cell (CAR-T cell) in which the expression of CD3 is reduced or eliminated and an adapter molecule that regulates the activity of the CAR-T cell. The "CAR T cell", the "first moiety",The "second moiety" or "adapter molecule" is as described above. Another aspect of the present invention provides a composition comprising a chimeric antigen receptor T cell (CAR-T cell) in which the expression of CD3 is reduced or eliminated and an adapter molecule that regulates the activity of the CAR-T cell. The composition may be a pharmaceutical composition. The composition may be a pharmaceutical composition for preventing or treating a T cell-derived tumor. Another aspect of the present invention provides a pharmaceutical composition for preventing or treating a T cell-derived tumor, comprising a chimeric antigen receptor T cell in which the expression of CD3 is reduced or eliminated, and administered in combination with an adapter molecule that regulates the activity of the CAR-T cell. The "CAR T cell", "first moiety", "second moiety" or "adapter molecule" is as described above. As used herein, the term "combination therapy" or "combined treatment" or "in combination" refers to any form of simultaneous or concurrent treatment using at least two separate therapeutic agents. The components of the combination therapy may be administered simultaneously, sequentially, in reverse order, or in any order. The components may be administered in different dosages, at different administration frequencies, or through different routes in an appropriate manner. As used herein, the term "administration" means introducing a given substance into a subject in an appropriate manner, and the "subject" means any living organism, including humans, such as rats, mice, and livestock, that may have a metabolic disease or side effects of a metabolic regulator. As a specific example, it may be a mammal, including humans. The term "administered simultaneously" as used herein is not particularly limited, and means that the components of the combination therapy are administered substantially simultaneously, for example, as a mixture or in an immediately subsequent order. The term "administered sequentially" as used herein is not particularly limited, and means that the components of the combination therapy are not administered simultaneously,Means that the administrations are administered one by one or in clusters with a specific time interval between administrations. The time intervals may be the same or different between the administrations of each component of the combination therapy and may be selected, for example, in the range of 2 minutes to 96 hours, 1 day to 7 days, or 1 week, 2 weeks, or 3 weeks. Typically, the time intervals between administrations may range from several minutes to several hours, for example, 2 minutes to 72 hours, 30 minutes to 24 hours, or 1 to 12 hours. Additional examples include time intervals in the range of 24 to 96 hours, 12 to 36 hours, 8 to 24 hours, and 6 to 12 hours. As used herein, the term "disease" may mean a pathological condition, in particular cancer, an infectious disease, an inflammatory disease, a degenerative disease, a disease involving cell death, and graft rejection. As used herein, the term "treatment" may refer to or include the alleviation, inhibition of progression, or prevention of a disease, disorder, or condition, or one or more symptoms thereof, and the term "active ingredient" or "pharmaceutically effective amount" may mean any amount of a composition used in the course of practicing the invention provided herein that is sufficient to alleviate, inhibit progression, or prevent a disease, disorder, or condition, or one or more symptoms thereof. As used herein, the terms "administering," "introducing," and "implanting" are used interchangeably and may mean the placement of a composition according to an embodiment into a subject by a method or route that results in at least partial localization of the composition to a desired site in an embodiment. In one embodiment, the term "transplanting" may refer to any suitable route that delivers at least a portion of the cells or cellular components of the composition to a desired location in a viable subject. It can be administered by. The survival period of cells after individual administration can be as short as several hours, for example, 24 hours to several days, or as long as several years. The T-cell derived tumor is T-cell prolymphocytic leukemia,T-cell large granular lymphocytic leukemia, chronic lymphoproliferative disorder of NK cells, aggressive NK leukemia, systemic EBV-positive T-cell 1 lymphoproliferative disease of childhood, hydroa vaccini form-1 ike lymphoma, adult T-cell leukemia / lymphoma, extranodal NK / T-cell 1 lymphoma (nasal type), enteropathy-associated T-cell 1 lymphoma, hepatosplenic T-cell lymphoma (hepatosplenic T-cell 1 lymphoma), subcutaneous panniculitis-like T-cell 1 lymphoma, mycosis fungoides, Se'zary syndrome, primary cutaneous CD30-positive T-cell 1 lymphoproliferative disorders, lymphomatoid papulosis, primary cutaneous anaplastic large cell 1 lymphoma, primary cutaneous gamma / delta T-cell 1 lymphoma,It may be selected from the group consisting of primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell 1 lymphoma, primary cutaneous CD4-positive small 1 / medium T-cell 1 lymphoma, peripheral T-cell 1 lymphoma NOS (not otherwise specified), angioimmunoblastic T-cell 1 lymphoma, ALK-positive anaplastic large cell 1 lymphoma, and ALK-negative anaplastic large cell 1 lymphoma. The administration may be in combination with an additional anticancer agent. Additional examples of anticancer agents may include alkylating agents, antimetabolites, spindle inhibitor plant alkaloids, cytotoxic / antitumor antibiotics, topoisomerase inhibitors, antibodies, photosensitizers, and kinase inhibitors. Examples of such anticancer agents may include compounds used in targeted therapies and conventional chemotherapy. Also, examples of the above antibodies include alemtuzumab, apolizumab, acelizumab, atlizumab, bapineuzumab, bevacizumab, vivatuzumab mertansine, cantuzumab mertansine, cedelizumab, certolizumab pegol, cidfusituzumab, cidtuzumab, daclizumab, eculizumab, efalizumab, epratuzumab, erlizumab, felvizumab, fontolizumab, gemtuzumab ozogamicin, inotuzumab ozogamicin, ipilimumab, labetuzumab, lintuzumab, matuzumab, mepolizumab, motavizumab, motovizumab, natalizumab, nimotuzumab,Nolovizumab, numavizumab, ocrelizumab, omalizumab, palivizumab, pascolizumab, pekfucituzumab, pectuzumab, pertuzumab, pexelizumab, ralivizumab, ranibizumab, reslivizumab, reslizumab, resaivizumab, rovelizumab, ruplizumab, sibrotuzumab, siplizumab, sontuzumab, tacatuzumab tetraxetan, tadoxizumab, talizumab, tefibazumab, tocilizumab, toralizumab, trastuzumab, tucotuzumab selmoleukin, tucusituzumab, umavizumab, urtoxazumab, and visilizumab may be included. The composition according to the present invention may further comprise a pharmaceutically acceptable carrier. In the case of injections, buffers, preservatives, analgesics, solubilizers, isotonic agents, stabilizers, etc. can be mixed and used, and in the case of topical administration, bases, excipients, lubricants, preservatives, etc. can be used. The formulation of the pharmaceutical composition of the present invention can be prepared in various ways by mixing it with the pharmaceutically acceptable carriers described above. For example, in the case of injections, it can be prepared in the form of unit dosage ampoules or multiple dosage forms. In addition, the anticancer composition may typically include a surfactant that facilitates movement through a membrane. Such surfactants include those derived from steroids, cationic lipids such as N-[l-(2,3-dioleoyl)propyl-N,N,N-trimethylammonium chloride (DOTMA), or various compounds such as cholesterol hemisuccinate and phosphatidyl glycerol. In one specific example, the composition can be administered in a pharmaceutically effective amount to treat cancer cells or their metastasis, or to inhibit the growth of cancer. It may vary depending on various factors such as cancer type, patient's age, weight, nature and degree of symptoms, type of current treatment, number of treatments, form and route of administration, etc., and can be easily determined by a person skilled in the art. The composition according to the present invention may be administered together or sequentially with the above-mentioned pharmacological or physiological components,Additionally, it can be administered in combination with additional conventional therapeutic agents, and can be administered sequentially or simultaneously with the conventional therapeutic agents. Such administration can be single or multiple administrations. Taking all of the above factors into consideration, it is important to administer an amount that achieves the maximum effect with the minimum amount without side effects, and this can be easily determined by those skilled in the art. Another aspect of the present invention provides a method for preventing or treating a T-cell-derived tumor, comprising administering the complex or pharmaceutical composition to a subject. Another aspect of the present invention provides a method for producing a chimeric antigen receptor T cell (CAR-T cell) in which expression of CD3 is reduced or eliminated, comprising the steps of (a) downregulating expression of CD3 or a T cell receptor (TCR) in a T cell, and (b) introducing a chimeric antigen receptor (CAR) comprising an extracellular domain, a transmembrane domain, and an intracellular signaling domain, wherein the extracellular domain comprises an antibody or an antigen-binding fragment thereof that specifically binds to a second moiety of an adapter molecule, wherein steps (a) and (b) are performed in any order. The method for reducing or eliminating the expression of the CD3 or TCR may be performed by a genome editing technique including a CRISPR system, specifically, CRISPR / Cas9, TALEN, zinc finger nuclease, base editing and prime editing, or by a nucleic acid selected from the group consisting of antisense RNA, antagomir RNA, si RNA, shRNA and miRNA.

[0014]

Effect of the invention

[0015]

Brief description of the drawings

[0016]

Form for carrying out the invention

[0017] In order for CAR-T cells to recognize the tumor surface antigen CD3 and selectively kill tumors, (1) conjugated CAR-T cells were created to avoid fratricide between CAR-T cells by making the CAR-T cells themselves not express CD3, and (2) to minimize the immunodeficiency side effects in patients caused by CAR-T cells with CD3 removed killing normal T cells that express CD3. A schematic diagram of this concept is as follows.

[0018]

[0019] [Conjugated CD3-targeted CAR-T cells] Experimental materials

[0020] (1) Mouse

[0021] C57BL / 6CB6) mice were purchased from Orient Bio. NSG mice (NOD. Cg- Prkdcscid 112rgtmlWj 1 / SzJ) were purchased from Jackson Laboratory. All mice were housed in a specific pathogen-free (SPF) animal facility at Seoul National University College of Medicine (Seoul, Republic of Korea) and maintained in accordance with the guidelines of the Institutional Animal Care and Use Committee (IACUC).

[0022] (2) Cell line

[0023] Jurkat (human T-cell lymphoma) was purchased from ATCC (ATCC, Manassas, VA USA). Phoenix GP (Phoenix Eco) cell line was provided by Garry Nolan (Stanford University, USA). GFP-luciferase expressing cell line (Jurkat-Luc) was transduced into Jurkat cells with lentivirus for GFP-Luc expression (pLEF-Luc-GFP), and GFP-positive cells were isolated using a cell sorter (cell sorter, FACS Aria, Becton Dickinson). Then, a single cell line was established through limiting dilution. CD3-deficient Jurkat cell line was established by introducing in-del mutations into the CD3 gene expressed by the cell line using the CRISPR-Cas9 system. CD3-negative cells were isolated using a cell sorter, and then a single cell line was established through limiting dilution.

[0024] 1-1. Production of CAR-expressing retrovirus and lentivirus In the case of scFv used in conjugated CAR-T cells, Cot CAR scFv was derived from rabbit-derived anti-cot inine antibody (Cl in Chim Acta 2010; 411:1238-1242), Hi s CAR scFv was derived from mouse-derived anti-Hi s antibody (mutated 3D5 clone; J . Mol . Biol . (2002) 318 , 135-147), and Myc CAR scFv was derived from mouse-derived anti-Myc antibody (9E10 clone; FEES Letters 414 (1997) 33-38). The mouse CAR protein coding region consists of the signal peptide of the mouse immunoglobulin kappa chain, the antibody scFv, and the previously reported CAR backbone region (mouse CD28 extracellular region-transmembrane region-intracellular region, mouse CD3 zeta intracellular region; GenBank HM754222.1, Blood 2010: 116(20): 4099-4102). CAR cDNAs were produced by requesting DNA synthesis to Integrated DNA technologies (IDT), Korea. The retroviral vector for producing mouse CAR-T cells for CAR expression was produced by cloning the PuroR gene region downstream of the PGK promoter in the pMSCV-puro (Ckmtech, USA) retroviral vector and replacing it with the produced CAR cDNA. The human CAR protein coding region consists of the signal peptide of human GMCSF, scFv of anti-His antibody, extracellular region of human CD28, transmembrane region, and intracellular region of human CD3 zeta. The protein coding region cDNA was produced by requesting DNA synthesis from IDT, USA.The retroviral vector for human CAR-T cell expression was cloned using human CAR cDNA using pMSGV (Addgene Plasmid #64269). The lentiviral vector for human CAR-T cell expression was constructed by cloning human CAR cDNA into a partially modified pCDH-EF1 vector (Addgene Plasmid #72266).

[0025] 1-2. Production of retrovirus and lentivirus for CAR expression To obtain ecotrophic retrovirus for transduction of mouse T cells, the CAR construct was transfected into Phoenix GP cells using Lipofectamine 3000 (Invitrogen) together with the pMD2.G plasmid containing cDNA encoding vesicular stomatitis Indiana virus G protein (VSV-G) as a viral envelope protein. After 48 hours, the supernatant containing VSV-G pseudotyped retrovirus was harvested and transduced into Phenix Eco cells. After 3 to 5 days, the CAR-high-expressing Phoenix Eco cells were stained with anti-rabbit IgG (Jackson ImmunoResearch, West Grove, PA USA) for Cot CAR and anti-mouse I gG (Jackson ImmunoResearch, West Grove, PA USA) for His CAR & Myc CAR, and then sorted using FACS Ar ia (Becton Dickinson) to establish a retrovirus-producing cell line. The retrovirus culture supernatant produced from this cell line was concentrated 5 to 10 times using a centrifugal filter device (Amicon Ultra-100 kDa cutoff, Millipore, USA) and used. To obtain amphotropic retrovirus for transduction of human T cells, the PG13 cell line for virus production was used. Each retroviral plasmid was transfected into the Phoenix Eco cell line using Lipofectamine 3000 (Invitrogen). After 48 hours, the culture supernatant containing retrovirus was harvested and added to the PG13 cell line for transduction.Afterwards, the establishment of retrovirus production cell lines and virus production were carried out in the same manner as for retroviruses for mouse cells. To obtain lentivirus for transduction of human T cells, each lentivirus plasmid was transfected into 293T cell 1 1 ine (ATCC) together with three types of packaging DNA (pMD.2G, pMDLg / pRRE, pRSV-rev) using Lipofectamine 3000 (Invitrogen). After 24 and 48 hours, the culture supernatant containing the secreted lentivirus was harvested and filtered (0.45 × 1 filter) to remove cell residual particles, and concentrated 100-fold using an ultracentrifuge. This was then used as a lentivirus concentrate for producing CAR T cells.

[0026] 1.3 Production of human CD3-edited T cells using the CRISPR / Cas9 system

[0027] The CRISPR / Cas9 system was used as a method for CD3 gene editing. To use this system efficiently, the cDNA of the human CD3 gene-targeting guide RNA (sgRNAl~18) was cloned into a vector (PX458) containing Cas9 cDNA. The constructed plasmid was transfected into CD3-positive Jurkat cells via electroporation to perform CD3 gene editing. For CD3 gene editing in human primary T cells, white blood cells obtained through leukapheresis from normal individuals were added together with anti-CD3 antibody (0KT3, 10 / / g / mt, BioXcell) to a 24-well plate coated with anti-CD28 antibody (CD28.2, 2 / / g / mt, BD Biosciences), and then cultured for 48 hours to activate T cells. Afterwards, ribonucleoprotein (RNP), a complex of Cas9 protein (Cas9 protein, Thermo) and target guide RNA, was produced and gene editing was performed on T cells using electroporation. The gene-edited T cells were cultured for 24 hours in a culture medium without antibiotics and with hIL-2 (200 U / ml), and then transferred back to a culture medium with antibiotics and hIL-2 to perform T cell culture. The degree of CD3 protein removal through CD3 gene editing was confirmed 36 hours after gene editing by flow cytometry (FACS-Canto II, BD Biosciences) to determine the degree of CD3 protein expression or T cell receptor expression.

[0028] To remove human CD3 using the CRISPR-Cas9 system, 18 guide RNA sequences for the human CD3 ORF target region were designed, and then a plasmid that simultaneously expresses the guide ORF and Cas9 nuclease was constructed in Jurkat, a human acute T-cell leukemia cell line, and the gene was introduced using electroporation. A primary screening was conducted to verify whether CD3 was removed, and the results are shown in Fig. 1.

[0029] In the first screening, four guide RNA sequences with high efficiency were selected, and a second screening was conducted using mRNA transfection with high T cell gene transfer efficiency. To this end, sgRNA (guide RNA + scaffold RNA) and Cas9 mRNA were newly produced through an in vitro transcription reaction, and then an experiment was conducted to verify whether CD3 was removed in Jurkat using mRNA electroporation, and the results are shown in Fig. 2. In addition, the sequences of sgRNA7 and sgRNA15 are shown in the following table and Table 2, respectively.

[0030] Table 11

[0031] Table 2 As shown in Fig. 1 and Fig. 2, a high deletion efficiency was obtained compared to plasmid DNA transfection, and in particular, a high deletion efficiency of over 80% was observed for two types of sgRNA (sgRNA7 and sgRNA15). Next, for sgRNA7 with good deletion efficiency, CD3 deletion in human T cells was attempted through RNP (ribonucleoprotein) electroporation, which is known to be simpler and has good gene editing efficiency, and the results are shown in Fig. 3. As shown in Fig. 3, the complex of recombinant Cas9 protein and sgRNA7 was in We achieved CD3 deletion with an efficiency of over 70% in activated human T cells using electroporation produced in the form of RNP. As described above, we have effectively established a method for CD3 gene editing in human T cells using the CRISPR / Cas9 system.

[0032] 1.4 Exploration of the possibility of CD3 gene editing in various conjugated CAR-T cells To produce conjugated CAR-T cells, cotinine, a nicotine metabolite, and peptide epitopes 6XHis tag and myc tag were selected as candidates for epitope tags to be labeled on the anti-CD3 adapter antibody, and anti-cotinine CAR-T cells (Cot CAR-T cells), anti-6XHis tag CAR-T cells (His CAR-T cells), and anti-myc tag CAR-T cells (Myc CAR-T cells) were produced, respectively. Anti-cotinine CAR-T cells were produced by transducing a retrovirus carrying a CAR gene including an anti-cotinine antibody scFv (Korean Patent Publication No. 2018-0031727) into activated mouse T cells. In the same manner, retroviruses carrying a CAR gene including the scFv of a previously reported anti-myc tag antibody (c 1 one 9E10, FEES Letters 414 (1997) 33-38) and a CAR gene including the scFv of an anti-6xHis tag antibody (mutated clone 3D5, J. Mol. Biol. (2002) 318, 135-147) were constructed, and these retroviruses were transduced into activated mouse T cells to produce Myc CAR-T cells and His CAR-T cells. Specifically, for mouse CAR T cells, spleen and lymph node cells obtained from normal mice were added together with a-CD28 antibody (37.51, 2 / / g / mt, BD Biosciences) to a 24-well plate coated with a-CD3 antibody (145-2C11, 10w / mt, BioXcell), and T cells were activated. After 24 hours, T cells were transduced with concentrated retrovirus through spin infection in the presence of 6ug / ml polybrene (polybrene, Sigma Aldrich) at 24 °C, 2500 rpm, and 90 min. This procedure was repeated once more on the same day.After spin infection, T cells were further cultured for 48 hours in the presence of mouse IL-2 (30 U / mt, Gibco). The retrovirus-transduced T cells were washed twice and then expanded in fresh culture medium containing mouse IL-2 (20 U / mt) for 2-3 days to be used as CAR T cells. The expression of CAR protein on the cell surface was measured using flow cytometry after staining with a-rabbit IgG (Cot CAR), Q-mouse IgG (His CAR, Myc CAR), His-biotin (biotin-labeled 6xHis peptide), and fluorescently labeled streptavidin. Mouse CD3 gene-edited CAR- T cells were subjected to mouse CD3 gene editing using electroporation the day after retrovirus transduction. The expression of CAR protein on the surface of each of these cells was confirmed, and this is shown in Fig. 4a. In addition, in order to confirm whether it is possible to produce CAR-T cells with CD3 deletion for CAR-T cells for chemicals (cotinine) and peptides (6XHis tag or myc tag), transduction via CAR-retrovirus and CD3 deleting sgRNA / Cas9 mRNA transfection were performed sequentially, and CAR-T cells in which CAR expression and CD3 deletion were simultaneously induced were produced, which is shown in Fig. 4b. As shown in Figs. 4a and 4b, in the case of anti-cotinine CAR-T cells, approximately 50-70% of CD4 and CD8 positive cells were observed, and among the three CAR-T cells, the highest expression rate was confirmed in His CAR T cells. Through the above results, it was confirmed that CD3 gene editing using the CRISPR-Cas9 system was possible in all three types of CAR-T cells (Cot CAR-T, His CAR-T, and Myc CAR- T cells).

[0033] 1.5 Production of conjugated CAR-T cells To produce conjugated human CAR-T cells, the anti-His CAR gene used in the mouse CAR-T cell experiment was redesigned as a human CAR backbone, and then cloned into a retroviral vector for human CAR T cells. The produced retrovirus was genetically introduced into human T cells isolated from peripheral blood to produce His CAR-T cells. Specifically, white blood cells isolated from normal blood were added to a 24-well plate coated with anti-CD3 antibody together with anti-CD28 antibody, and then cultured for 48 hours to activate the T cells. The activated T cells were washed twice and then used for retroviral transduction. After coating with Retronectin (20 wt / mt, TaKaRa) overnight at 4°C, the washed 24-well plate was blocked with 2% BSA-DPBS for 30 minutes at 37°C and washed. Then, retrovirus concentrate Imt was added and centrifuged at 2000 x g and 32°C for 2 hours to attach the retrovirus to the bottom of the well. After removing the virus concentrate and washing the well, activated T cells (1X10 6(cells / mt) Imt was added to the well and the cells were attached to the retrovirus through centrifugation (lOOOxg, 32°C) for 10 minutes. Subsequently, the cells were cultured for 48 hours in the presence of human IL-2 (200U / mt, Pro leukin, Novartis). In the case of lentivirus transduction, lentivirus was added to the human T cell culture medium activated for 48 hours and co-cultured for 48 hours. The T cells transduced by the virus were washed twice to remove any remaining virus in the culture medium, and the culture medium containing human IL-2 (200U / mt) was added twice every 3 days (day 3 + day 3) to produce CAR T cells. Figure 5 is a graph analyzing the expression rate of 6xHis-CAR in human CAR T cells introduced with His tag. In addition, the amino acid sequence of each domain of His CAR-T cells is shown in Table 3 below.

[0034] Table 3 As shown in Fig. 5, the CAR expression rate was analyzed through flow cytometry, and it was confirmed that human anti-6xHis CAR T cells were successfully produced with a gene transfer efficiency of approximately 40%. Example 2. Production of anti-CD3 adapter antibody

[0035] 2.1 Production of adapter antibodies using anti-CD3 antibodies - In the case of chemical tags such as 0KT3, UCHT1 cotinine, it is difficult to maintain a constant conjugation efficiency because they must be conjugated to the adapter through a chemical reaction, and there is a disadvantage in that it is difficult to control the number of chemical molecules conjugated to one adapter (Drug Antibody Ratio, DAR). On the other hand, in the case of peptide epitopes such as 6xHis tag or myc tag, the peptide can be linked to the recombinant antibody ORF gene through genetic recombination using an epitope tagging method, so there is an advantage in that it can maintain 100% conjugation efficiency and a 1:1 DAR in which one tag is bound to one adapter. In particular, 6xHis peptides have been widely used as epitope tags for protein purification, and thus a system for mass purification of antibody drugs using them is well-established. Therefore, it has the advantage of being able to achieve two purposes simultaneously: as an adapter epitope tag for conjugated His CAR T cells and as an epitope tag for adapter purification using a single epitope tag. In addition, it has the advantage of relatively low immunogenicity in vivo. Therefore, the 6xHis tag was used in an anti-CD3 adapter antibody. A 6xHis-tagged adapter antibody was produced in the form of a scFv using the commercially available anti-human CD3 antibody 0KT3 (Muromonab) sequence or UCHT1 sequence. A construct was created by connecting the VL and VH regions of OKT antibody or UCHT1 antibody with a linker ((GGGGS)J) (scFv), then connecting the human immunoglobulin kappa constant region (CK) for separation and stability, and directly connecting a 6xHis tag to the C-terminus, or connecting a short linker peptide and a 6xHis tag. A schematic diagram of this is shown in Fig. 6, and the scFv amino acid sequences of 0KT3 are shown in Tables 4 and 5, respectively.At this time, Table 4 shows the amino acid sequence of scFv (0KT3-Ck-His) that does not include a linker after the Ck domain, and Table 5 shows the amino acid sequence of scFv (0KT3- Ck- L- His) that includes a linker after the Ck domain. In addition, the amino acid sequence of scFv (UCHTl-Ck-His) of UCHT1 is shown in Table 6 below. After transfecting the HEK293K cell line with the plasmid expressing the construct, purification was performed through affinity chromatography, and the results are shown in Figure 7.

[0036] Table 4

[0037] Table 5

[0038] Table 6 In addition to the scFv form, as part of an effort to increase the CAR binding affinity of the adapter antibody, a -His adapter antibody was also produced in Fab form to have two 6xHis tags and to be able to bind to 6xHis CAR in a bivalent form. A schematic diagram of this is shown in Fig. 8, and the amino acid sequences of Fab (0KT3-Fab-His, UCHT1-Fab-His) of 0KT3 and UCHT1, respectively, are shown in Tables 7 and 8 below.

[0039] Table 7

[0040] Table 8

[0041] 2.2 Production of adapter antibodies using novel anti-CD3 antibodies - 1-4-2, 1-4-7 Anti-human CD3 antibodies were further screened for CD3 binding antibodies using animal immune antibody libraries in addition to the above 0KT3 or UCHT1 antibodies. Specifically, human CD3 gamma / epsilon and delta / epsilon extracellular heterodimer proteins were mixed with adjuvant and immunized 10 chickens four times at two-week intervals, and then the spleen, bone marrow, and synovial bursa of the chickens were collected, and total RNA was isolated, cDNA was synthesized, variable light chain and heavy chain gene PCR was performed, and a vector for phage display was used. P A chicken immune antibody library was constructed by cloning into Comb3XSS. Subsequently, bio-panning was performed to screen antibody clones that specifically bind to human CD3 protein. After separating and purifying positive antibody clones in the form of scFv, two antibodies (clones 1-4-2 and 1-4-7) that bind to CD3(+) Jurkat cells were finally selected. The selected antibodies were cloned into an animal cell expression vector to produce them in the form of scFv-Ck-6xHis fusion proteins and transformed into HEK293F cells. After shaking culture for 5 days, the culture medium was harvested and affinity purified using KappaSelect beads, and antibody expression was confirmed by SDS-PAGE. That is, for the novel screening antibodies 1-4-2 and 1-4-7, scFv and Fab-type adapter antibodies were also shown, and their amino acid sequences are shown in Tables 9 to 12 below, and in particular, the results of SDS-PAGE analysis of the scFv (1-4-2-Ck-His, 1-4-7-Ck-His) of 1-4-2 and 1-4-7 are shown in Figure 9.

[0042] 【Table 2

[0043]

[0044] Table 10

[0045] Table 11

[0046] Table 12 Specifically, anti-human CD3 (UCHT1, 1-4-2, 1-4-7) Fab-His antibody and anti-human CD3 (0KT3, UCHT1, 1-4-2, 1-4-7) scFv-His antibody were expressed through the culture medium by cloning the genes into the antibody expression vector pCEP4 and transducing 293F cells. The expressed antibodies were separated and purified through affinity purification. For the purified antibodies, cell surface binding was verified through electrophoresis using SDS-polyacrylamide gel and flow cytometry on a cell line expressing human CD3. The binding of CD3-positive cells and adapter antibodies was verified using 1X10 5The cells / lug adapter was incubated at 4 °C for 1 hour. After washing to remove free adapter antibody, the adapter antibody was stained with anti-His antibody (J096G46, Biolegend) and analyzed using flow cytometry. In order to analyze whether the expressed and purified anti-human CD3 antibody binds to the CD3 protein expressed on the surface of T cell tumors, the binding of the manufactured 0KT3-His scFv (0KT3-Ck-His, 0KT3-Ck-L-His) and UCHT1-Fab-His to Jurkat T cells was analyzed by flow cytometry. The results are shown in Fig. 10. In the same way, flow cytometry was performed on the scFv and Fab of 1-4-2, and the scFv and Fab of 1-4-7, and the results are shown in Fig. 11. As shown in Figure 10, it was confirmed that scFv and Fab prepared with anti-CD3 antibodies specifically bound to the Jurkat cell line. As shown in Figure 11, it was confirmed that they specifically bound only to the Jurkat cell line, but not to the CD3-negative cell line (CD3-deleted Jurkat). Experimental Example 1. Antitumor activity of anti-CD3 adapter antibodies and human conjugated CAR-T cells To verify in vitro whether the complex of the 6xHis-tagged anti-CD3 adapter antibody and human anti-6xHis CAR-T cell (His CAR-T cell) produced in Example 2 above recognizes and activates CD3-positive T cell tumors, Jurkat leukemia cells were co-cultured with 0KT3 scFv-Ck-6xHis (0KT3-Ck-His), 0KT3 scFv-Ck-6xHis (0KT3-Ck-L-His), and mouse His CAR-T cells, and the amount of IFN-r secreted by the CAR-T cells was measured by ELISA. As a result, it was confirmed that the function of the CAR-T cells was activated as the IFN-r production of the T cells increased in the presence of the two adapters. In addition, the effect showed a dose-dependency in which the effect further increased as the adapter dose was increased fivefold. The results are shown in Fig. 12a. Next, 0KT3 scFv- Ck- 6xHis (0KT3- Ck- His), which has a slightly higher activity among the two adapters, was co-cultured with Jurkat leukemia cells and human His CAR-T cells, and the amount of IFN- r secreted by CAR-T cells was measured by ELISA. In addition, an experiment was conducted to confirm the cytotoxicity assay for Jurkat tumor cells, and the results are shown in Fig. 12b. Using the same method, the scFv adapter antibody was converted to the Fab-His form verified in the mouse conjugated CAR T cell model, and the cytotoxicity test for Jurkat tumor cells was repeated, and the results are shown in Fig. 13. In addition, Fab-His adapter antibodies were produced using UCHT1 antibody, another clone of anti-CD3 antibody, and two antibodies (1-4-2 and 1-4-7) selected through screening, and the in vitro activity and cell killing capacity of conjugated CAR T cells were analyzed using the same method. The results are shown in Fig. 14 (UCHT1) and Fig. 15 (1-4-2, 1-4-7), respectively.As shown in Figures 12 to 15, conjugated CAR T cells were activated in a concentration-dependent manner only in the presence of anti-CD3 adapter antibodies, produced large amounts of IFN-r, and exhibited tumoricidal activity. Through the above results, the cancer antigen recognition ability, specific activation, and cell killing ability of the anti-CD3 adapter antibody and CAR T cell complex were confirmed. Tumor killing ability, cytokine production ability, and anti-fratricide function of conjugated CAR T cells To test whether conjugated CAR-T cells were activated by recognizing tumor cells through the adapter antibody, tumor cells were pre-incubated with the adapter antibody for 1 hour, and then unbound free adapter antibody was removed through washing. Afterwards, the tumor cells with the adapter attached were used together with the conjugated CAR-T cells in an in vitro experiment. For luciferase-based tumor killing activity measurement, CAR T cells (1.2X10. 3 ~ 7.5 X10 5 cells / 100M / well) were added to Jurkat-Luc cells (3X104cells / 50M / well) at various ratios (CAR-T: Jurkat=0.04∼25:1) and co-cultured overnight in a 96-well plate. Then, D-Luciferin (600 / zg / mt, Pr omega) 50 / z£ was added and incubated at 37°C for 10 minutes to induce luciferase enzyme activity in Jurkat-Luc cells that survived until then. The luminescence of these cells was measured using a Luminometer (Tecan), and the tumor killing ability of CAR T cells was measured by calculating the survival rate of tumor cells by comparing it with the luminescence of Jurkat-Luc cells that were not treated with CAR T cells.

[0047] To measure the cytokine production ability of CAR T cells, CAR T cells and target cells (Jurkat cells) were mixed at a ratio of 1:5 (CAR-T: 3X10 4 cells, Jurkat: 1.5X105cells) were mixed and co-cultured in a 96-well plate for 24 hours, and then the culture supernatant was harvested. The amount of IFN- x secreted into the supernatant was measured by ELISA (mouse IFNx, human IFNy ELISA kit, BD Biosciences). Experimental Example 2. Analysis of fratricide phenomenon of human conjugated CAR-T cells When conjugated CAR T cells are combined with anti-CD3 adapter antibodies, fratricide phenomenon occurs in which conjugated CAR T cells target CD3 on the surface of other CAR T cells and kill each other. It was verified in = whether CD3 removal by gene editing can prevent this fratricide phenomenon. Specifically, anti-6xHis- CAR T cells were cultured alone (control group) or together with 6xHis-tagged anti-CD3 adapter antibody and human anti-6xHis- CAR T cells (experimental group), and the viability of CAR T cells was analyzed by flow cytometry at 24, 48, and 72 hours after culture at 37°C, respectively. The viability analysis was performed by analyzing the ratio of 7-AAD-negative cells (live cells) using 7-AAD, a fluorescent substance that binds to the day of dead cells, and the results are shown in Fig. 16. As shown in Fig. 16, it was confirmed that the viability of anti-6xHis- CAR T cells was significantly reduced in the presence of anti-CD3 adapter antibody, thereby confirming that fratricide was induced. Therefore, it was experimentally confirmed that conjugated human CAR T cells require the removal of CD3 protein by CD3 gene editing through anti-CD3 adapter antibody. Experimental Example 3. Production of human CD3-edited conjugated CAR-T cells and verification of anti-fratricide function As confirmed in Experimental Example 2 above, in order to produce CAR T cells that exclude fratricide, human T cells in which the CD3 gene is edited and at the same time expressing the conjugated CAR were produced.Specifically, as a result of sequentially performing CD3-deleting sgRNA / Cas9 protein RNP transfection and CAR-retrovirus transduction on human T cells isolated from peripheral blood, human T cells were produced in which CAR expression and CD3 removal were simultaneously induced, and the expression of CAR and CD3, respectively, was confirmed by flow cytometry. The flow cytometry results during the process of CD3 removal and CAR introduction are shown in Fig. 17. In addition, in order to verify the allogeneic killing prevention function of conjugated CAR T cells through CD3 removal, a cell viability analysis experiment through 7AAD fluorescence staining was conducted. Specifically, they were divided into (1) DHis CAR T cells, (2) His CAR T cells + anti-CD3 adapter antibody (0KT3-His), (3) CD3-deleted His CAR T cells, and (4) CD3-deleted His CAR T + anti-CD3 adapter antibody (0KT3-His) cells, cultured at 37°C for 24 hours, and then cell viability analysis was performed through 7AAD fluorescence staining. In addition, the CD3 expression levels of (1) DHis CAR T cells, (2) His CAR T cells + anti-CD3 adapter antibody (0KT3-His), and (3) CD3-deleted His CAR T + anti-CD3 adapter antibody (0KT3-His) cells were analyzed by flow cytometry. The results are shown in Fig. 18. As shown in Fig. 17, it was confirmed that human CD3 gene-edited conjugated CAR T cells were successfully produced. As shown in Fig. 18, it was confirmed that the viability of CD3 gene-edited CAR T cells (73.1%) was significantly higher than that of CAR T cells without CD3 removal (43.3%) in the presence of the anti-CD3 adapter antibody (73.1% vs 43.3% under 24-hour culture conditions). In addition, it was confirmed that CD3 expression was also significantly decreased in the (4) CD3-deleted His CAR T + anti-CD3 adapter antibody (0KT3-His) group.Through the above results, it was confirmed that anti-CD3 conjugated CAR T cells that exclude fratricide were successfully produced through CD3 gene editing. Experimental Example 4. Analysis of anti-tumor activity of anti-CD3 adapter antibody and human conjugated CAR-T cells (in vivo).

[0048] 4.1 Establishment of proliferation conditions for human CAR T cells

[0049] In order to confirm the tumor treatment effect using CD3 gene-edited conjugated human CAR T cells and anti-CD3 adapter antibodies in vivo (in r / w), it is essential to secure a sufficient number of T cells. Therefore, it is necessary to establish conditions for mass proliferation of human CAR T cells. First, CD3-positive cells were removed to increase the separation and purification efficiency of CD-negative cells. Then, to secure a sufficient number of CD3 gene-edited CAR T cells required for the experiment, secondary cell proliferation was induced by treating hlL-2 (300 U / ml) for 4 days after separation and purification. A schematic diagram of the established CD3 gene-edited conjugated CAR T cell proliferation conditions is shown in Fig. 19. The human CD3 gene-edited conjugated CAR T cells produced through CRISPR / Cas9 transfection and CAR transduction in Experimental Example 3 include some CD3-positive cells. To prevent fratricide and increase the targeting efficiency of CAR T cells, a process of purifying CD3-negative cells was required. To this end, negative selection was performed using MACS (magnetic activated cell sorting) using anti-human CD3 magnetic beads. Specifically, in the case of human CD3 gene-edited CAR T cells, 2 days after cell activation, CD3 protein gene editing was performed via electroporation, followed by retroviral or lentiviral transduction to produce CD3 gene-edited conjugated CAR-T cells. For the CD3-positive cells remaining after gene editing, only CD3-negative cells were sorted using magnetic activated cell sorting (MACS). Five days after CD3 in T cells was removed using CRISPR / Cas9 gene-editing technology, CD3 gene-edited T cells were cultured with anti-human CD3 antibodies attached to magnetic microspheres.Afterwards, the cells cultured with magnetic microbeads-antibody (hCD3 microbeads, Mil tenyi) were passed through a strong magnetic separator. CD3-positive cells that had not been gene-edited were attached to the magnetic separator because of the magnetic microbeads-antibody attached to them. On the other hand, CD3-negative cells were separated by passing through the separator without attaching to the separator. The separated CD3-negative cells were further cultured in a medium containing hIL-2 (200 U / ml). The expression of the CAR protein on the cell surface was determined by staining the proliferated CAR T cells with HiS-biotin and APC-labeled SA (SA-APC, BioLegend) 5 days after retroviral transduction, and then flow cytometry (FACS-Canto II, BD Biosciences). We confirmed that CD3-negative human CAR T cells could be effectively isolated and purified by subjecting human CD3 gene-edited conjugated CAR T cells to the Ant i-CD3 MACS process, and whether the CD3-negative state was maintained in the T cell population after the secondary cell expansion period. The results are shown in Figs. 20 and 21. As shown in Fig. 20, it was confirmed that the CD3-negative state and the level of CAR expression were mostly maintained in the T cell population after the secondary cell expansion period. As shown in Fig. 21, on the first human T cell isolation and activation day (day 0: IxlO. 6 CD3 gene-edited conjugated CAR T cells proliferated 20-fold during a total of 11 days of culture (day 1: approximately 2xlO 7 T cells) were finally obtained.

[0050] 4.2 Identification and analysis of the anti-tumor ability of human CAR T cells (OKT3-scFV-His) (in vivo) To verify the anti-cancer efficacy against T cell lymphoma in vivo using an anti-CD3 adapter antibody and CD3 gene-edited conjugated CAR T cells, a human-derived T cell tumor overexpressing luciferase (Jurkat-Luc cells) was injected into immunodeficient NSG mice to establish a xenogeneic mouse tumor model experiment model. Specifically, 3×10 6 cells of the CD3-positive Jurkat-Luc cell line (luciferase-transfected) were injected into NSG mice via intravenous injection. Three days after Jurkat-Luc injection, 3×10 6Cells were injected intravenously. The first anti-CD3 adapter antibody (0KT3(scFv)- Ck-His) was administered 4 hours before CAR T cell injection at 20 µg per mouse, and then administered at 2-day intervals for a total of 8 times (Fig. 22). Bioluminescence images were taken once a week to measure the size of tumor cells using IVIS 100 (PerkinElmer, Waltham, MA USA). Each mouse was injected intraperitoneally with 2 mg of D-Lucifer in 100 µl of saline. The size of tumor cells was measured via IVIS 100 10 minutes after intraperitoneal injection. The experiments were conducted by dividing the NSG mice into three groups: ① a group injected with only the DJurkat cell line, ② a group injected with only CD3 gene-edited conjugated CAR T cells without anti-CD3 adapter antibodies, and ③ a group injected with anti-CD3 adapter antibodies + CD3 gene-edited conjugated CAR T cells. The survival rate of the mouse models up to 60 days after tumor cell injection was analyzed. The results are shown in Fig. 23. As shown in Fig. 23, compared to when CD3 gene-edited conjugated CAR T cells were administered alone, when anti-CD3 adapter antibodies were administered together, a significant reduction in tumors was observed, and it was confirmed that the survival rate of the mice also increased significantly.

[0051] 4.3 Analysis of antitumor activity of human CAR T cells (UCHT1- Fab-His) (in vivo) In addition to the 0KT3(scFv)- Ck-His adapter antibody used in Experimental Example 4.2, another type of anti-CD3 adapter antibody, UCHT1- Fab-His, was used to demonstrate antitumor activity in vivo. A Xenogeneic mouse tumor model was constructed by injecting Jurkat-Luc cells, a human-derived T cell tumor, into DNLGO and immunodeficient NSG mice. Specifically, 3xl0 CD3-positive Jurkat-Luc cell lines were injected into NSG mice. 6 Cells were injected intravenously. Three days after Jurkat injection, 3xl0 CD3 gene-edited human CAR T cells were produced using human T cells. 6Cells were injected intravenously. UCHTl-Fab-His adapter antibody was administered as the first anti-CD3 adapter antibody 4 hours before CAR T cell injection at 20 ug per mouse, and was then administered repeatedly 7 times at 2-day intervals. After a 2-week rest period, the anti-CD3 adapter antibody was administered 8 times at 2-day intervals again, for a total of 16 times (Fig. 24). Each NSG mouse was divided into ① a group injected with only the Jurkat cell line, ② a group injected with only CD3 gene-edited conjugated CAR T cells without anti-CD3 adapter antibody, ③ a group injected with only anti-CD3 adapter antibody without CD3 gene-edited conjugated CAR T cells, and © a group injected with anti-CD3 adapter antibody + CD3 gene-edited conjugated CAR T cells. The experiment was conducted and the survival rate of the mouse model was analyzed for up to 80 days after tumor cell injection. The results are shown in Fig. 25. As shown in Fig. 25, when the CD3 gene-edited conjugated CAR T cells were administered together with the anti-CD3 adapter antibody, a significant reduction in tumors was observed, similar to the results of the experiment using the 0KT3 scFv adapter, compared to when the CD3 gene-edited conjugated CAR T cells were administered alone, and it was confirmed that the survival rate of the mice was also greatly increased. Through the above results, we confirmed the excellent anti-tumor activity in vivo using the anti-CD3 antibody adapter antibody (0KT3-scFv and UCHT1-Fab), confirming that CD3-conjugated CAR T cells can be provided as a therapeutic agent for T-cell tumors. In addition, we confirmed that various anti-CD3 antibodies can be used as adapter antibodies for CD3-conjugated CAR T cells. Experimental Example 5. Evasion of immunodeficiency toxicity (normal T cell toxicity) of human conjugate CAR T cells To confirm the evasion of toxicity against normal T cells by anti-human CD3 adapter antibody and human conjugate CAR T cell complex, the killing ability against normal T cells was confirmed using normal T cells as target cells.At this time, since the immune deficiency prevention ability cannot be verified in vivo (in vivo), it was confirmed through in vitro experiments. Specifically, after using T cells of human peripheral blood mononuclear cells (PBMC) as target cells and adding anti-human CD3 antibody and / or CD3 gene-edited human conjugate CAR T cells, flow cytometry was used to analyze whether normal T cells were killed, and the results are shown in Fig. 26. As shown in Fig. 26, the T cells expressing CD3 rapidly decreased only when the anti-human CD3 adapter antibody was present, through which the killing of normal T cells by CAR T cells was confirmed. In the situation without the adapter antibody, the numerical value of T cells expressing CD3 positively was maintained regardless of the presence or absence of CD3 conjugate CAR T cells, indicating that normal T cells were not killed. Through this, it was indirectly confirmed that the toxicity to normal T cells can be regulated according to the administration of the adapter antibody in actual vivo, and the side effect of immune deficiency toxicity of the CD3 conjugate CAR T cells of the present invention can be avoided. Experimental Example 6. Production of conjugate CAR-T cells using humanized antibodies.

[0052] To commercialize CD3 gene-edited conjugated CAR T cells, humanization and affinity maturation of the mouse-derived anti-6xHis scFv (mutated 3D5) used in the His CAR were performed. Antibody humanization and affinity maturation For humanization and affinity maturation of the mouse anti-His scFv antibody, first, six complementarity determining regions (CDRs) showing the most suitable sequence similarity were grafted onto the human germline genes of IGHV1-18 and IGKV2-28. Simultaneously, several amino acid sites in the framework regions (FRs) were altered to remove post-translational modifications and perform reverse mutations. Subsequently, a sub-library of humanized antibodies containing site-directed mutations in the six CDRs was constructed for affinity maturation. Antibodies were produced using the Exp i293 expression system, affinity purified, and ELISA was performed to determine their binding affinity to the antigen (WuXi Biologies). SPR binding affinity measurement of humanized antibodies.

[0053] Binding kinetics, rate, and affinity constants were generated using a Biacore 8K SPR system (Cytiva) equipped with a CM5 sensor chip. To prepare the capture surface for anti-His antibodies, streptavidin was immobilized, followed by capture with a biotin-conjugated 6xHis peptide. The antibody was serially diluted 2-fold with 1x PBS and injected at a flow rate of 30 μL / min for 3 minutes, followed by a 10-minute dissociation step. The surface was regenerated with 10 mM glycine, pH 1.5. Kinetics were analyzed using Biacore 8K Evaluation Software version 10 (Cytiva). Figure 27 shows the antigen affinity of the humanized anti-His antibody. The final humanized antibody scFv exhibited an antigen affinity approximately 5.8-fold higher than that of the original scFv, demonstrating successful humanization. Next, using humanized anti-6xHis scFv, a CAR gene similar to the existing His CAR was cloned into a lentiviral vector to produce lentivirus, and then human T cells were transduced to produce humanized His CAR-T cells (huHis CAR-T cells). CAR expression on the surface of huHis CAR-T cells was confirmed by flow cytometry, and the results are shown in Fig. 28. As a result of verifying the in vitro activity of conjugated CAR T cells using the produced huHis CAR-T cells and the UCHTl-Fab-His adapter, it was confirmed that huHis CAR-T cells also showed T cell activation and tumor cell killing ability in the presence of the adapter antibody, similar to the existing His CAR-cells (Fig. 29). Therefore, by confirming that it is possible to produce conjugated humanized CAR-T cells that can be applied clinically, the commercialization potential of the present invention was proven.

[0054] Table 13 Through the above results, not only can the combined administration of anti-CD3 adapter antibody and CD3-edited conjugated CAR T cells achieve a strong therapeutic effect on T-cell tumors, but also the possibility of avoiding immunodeficiency side effects caused by normal T-cell toxicity by implementing conjugated CAR T was proven. The description of the present invention described above is for illustrative purposes, and a person having ordinary skill in the art to which the present invention pertains will understand that the present invention can be easily modified into other specific forms without changing the technical spirit or essential characteristics of the present invention. Therefore, it should be understood that the embodiments described above are exemplary in all aspects and not limiting.

Claims

【Scope of Claims】 【 Claim 11 A pharmaceutical composition for preventing or treating a T cell-derived tumor, comprising a chimeric antigen receptor T cell (CAR-T cell) in which CD3 expression is reduced or eliminated and an adapter molecule that regulates the activity of the CAR-T cell, wherein the adapter molecule comprises (a) a first moiety that binds to CD3 on a target cell and (b) a second moiety that specifically binds to an extracellular domain of a chimeric antigen receptor, and wherein the CAR-T cell expresses a chimeric antigen receptor, the chimeric antigen receptor comprising (i) an extracellular domain comprising an antibody or an antigen-binding fragment thereof that specifically binds to the second moiety of the adapter molecule, (ii) a transmembrane domain, and (iii) an intracellular signaling domain.

2. A pharmaceutical composition for preventing or treating a T cell-derived tumor, comprising a chimeric antigen receptor T (CAR T) cell in which CD3 expression is reduced or eliminated, wherein the pharmaceutical composition is administered in combination with an adapter molecule capable of modulating the activity of the CAR-T cell, wherein the adapter molecule comprises (a) a first moiety that binds to CD3 on a target cell and (b) a second moiety that specifically binds to an extracellular domain of the chimeric antigen receptor, and wherein the chimeric antigen receptor comprises an extracellular domain, a transmembrane domain, and an intracellular signaling domain, wherein the extracellular domain comprises an antibody or an antigen-binding fragment thereof that specifically binds to the second moiety of the adapter molecule.

3. A pharmaceutical composition according to claim 1 or claim 2, wherein the first moiety is selected from the group consisting of an antibody, an antigen-binding fragment, an affibody, a diabody, and an aptamer.

4. A pharmaceutical composition according to any one of claims 1 to 3, wherein the antigen-binding fragment is Fab, Fab', F(ab')2, Fv, scFv or single-domain antibody (sdAB).

5. A pharmaceutical composition according to any one of claims 1 to 4, wherein the second moiety is a peptide tag or a hapten tag.

6. A pharmaceutical composition according to any one of claims 1 to 5, wherein the tag is selected from the group consisting of a His tag, a Myc tag, a cotinine tag, a FITC tag, a biotin tag, a Leucin zipper tag, a Flag tag, an Xpress tag, an Avi tag, a calmodulin binding peptide (CBP) tag, a polyglutamate tag, an HA tag, a Strep tag, Softag 1, Softag 3, and a V5 tag.

7. A pharmaceutical composition according to any one of claims 1 to 6, wherein the first moiety is an anti-CD3 antibody or an antigen-binding fragment thereof, and / or the second moiety is a His tag. 【

8. An antibody according to any one of claims 1 to 7, wherein the first moiety comprises a light chain variable region comprising 0KT3, UCHT1, a CDR1 consisting of the amino acid sequence of SEQ ID NO: 23, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 24, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 25, and a heavy chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 26, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 27, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 28; A pharmaceutical composition selected from the group consisting of antibodies comprising a light chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 32, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 33, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 34, and a heavy chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 35, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 36, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 37; and a light chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 67, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 68, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 69, and a heavy chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 70, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 71, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 72, wherein the second moiety is a His tag. 【A pharmaceutical composition according to any one of claims 1 to 8, wherein the reduction or elimination of CD3 expression of CAR-T cells is achieved by removing CD3 or T cell receptor (TCR) of CAR-T cells.

10. In any one of claims 1 to 9, the T-cell derived tumor is T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, chronic lymphoproliferative disorder of NK cells, aggressive NK Aggressive NK leukemia, systemic EBV-positive T-cell lymphoproliferative disease of childhood, hydroa vaccine-like lymphoma, adult T-cell leukemia / lymphoma, extranodal NK / T-cell lymphoma (nasal type), enteropathy-associated T-cell lymphoma, hepatosplenic T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, mycosis fungoides fungoides), Se'zary syndrome, primary cutaneous CD30-positive T-cell lymphoproliferative disorders, lymphomatoid papulosis, primary cutaneous anaplastic large cell lymphoma, primary cutaneous gamma / delta T-cell lymphoma, primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma,A pharmaceutical composition selected from the group consisting of primary cutaneous CD4-positive small / medium T-cell lymphoma, peripheral T-cell lymphoma NOS (not otherwise specified), angioimmunoblastic T-cell lymphoma, ALK-positive anaplastic large cell lymphoma, and ALK-negative anaplastic large cell lymphoma.

11. A complex comprising a chimeric antigen receptor (CAR-T cell) having reduced or eliminated CD3 expression and an adapter molecule that regulates the activity of the CAR-T cell, wherein the adapter molecule comprises (a) a first moiety that binds to CD3 on a target cell and (b) a second moiety that specifically binds to an extracellular domain of the chimeric antigen receptor, and wherein the CAR-T cell expresses a chimeric antigen receptor comprising (i) an extracellular domain comprising an antibody or antigen-binding fragment thereof that specifically binds to the second moiety of the adapter molecule, (ii) a transmembrane domain, and (iii) an intracellular signaling domain.

12. A method for preventing or treating a T cell-derived tumor, comprising administering to a subject a pharmaceutical composition according to any one of claims 1 to 10 or a complex according to claim 11.

13. A chimeric antigen receptor T cell (CAR-T cell) in which CD3 expression is reduced or eliminated, wherein the CAR-T cell expresses a chimeric antigen receptor comprising (i) an extracellular domain comprising an antibody or an antigen-binding fragment thereof that specifically binds to a second moiety of an adapter molecule, (ii) a transmembrane domain, and (iii) an intracellular signaling domain, wherein the adapter molecule comprises (a) a first moiety that binds to CD3 on a target cell and (b) a second moiety that specifically binds to the extracellular domain of the chimeric antigen receptor.

14. A CAR-T cell according to claim 13, wherein the first moiety is an anti-CD3 antibody or an antigen-binding fragment thereof and / or the second moiety is a His tag.

15. A CAR-T cell according to claim 13 or claim 14, wherein the second moiety is a His tag, and the antibody or antigen-binding fragment thereof that specifically binds to the His tag has an amino acid sequence of SEQ ID NO:

63.

16. A CAR-T cell having an amino acid sequence of SEQ ID NOs: 63 to 65 according to any one of claims 13 to 15.

17. (a) a step of downregulating the expression of CD3 or T cell receptor (TCR) in T cells, and (b) a step of introducing a chimeric antigen receptor (CAR) comprising an extracellular domain, a transmembrane domain, and an intracellular signaling domain, wherein the chimeric antigen receptor comprises an antibody or an antigen-binding fragment thereof that specifically binds to a second moiety of an adapter molecule, into a T cell, wherein steps (a) and (b) are performed in any order, wherein the adapter molecule comprises (i) a first moiety that binds to CD3 on a target cell and (ii) a second moiety that specifically binds to an extracellular domain of the chimeric antigen receptor.

18. In claim 17, the step of down-regulating the expression of CD3 or T cell receptor (TCR) in the (a) T cell is performed by a genome editing technique, shRNA, siRNA or miRNA. 【Claim 1: A method according to claim 17 or claim 18, wherein the genome editing technique is CRISPR (clustered regularly interspaced short palindromic repeats) / Cas 9, TALEN, zinc finger nuclease, base-editing, or prime— editing to remove CD3 or T cell receptor (TCR) of CAR-T cells.

20. A method for removing CD3 or T cell receptor (TCR) of CAR-T cells by CRISPR / Cas9 technique using a guide sequence comprising a polynucleotide sequence of SEQ ID NO: 57 or SEQ ID NO: 58 according to any one of claims 17 to 19.

21. (a) a first moiety that binds to CD3 on a target cell; and (b) An adapter molecule for regulating the activity of a chimeric antigen receptor T cell (CAR-T cell), comprising a second moiety that specifically binds to the extracellular domain of a chimeric antigen receptor. 【

22. An adapter molecule according to claim 21, wherein the first moiety is selected from the group consisting of an antibody, an antigen-binding fragment, an affibody, a diabody, and an aptamer.

23. An adapter molecule according to claim 21 or claim 22, wherein the antigen-binding fragment is Fab, Fab', F(ab')2, Fv, scFv or single-domain antibody (sdAB).

24. An adapter molecule according to any one of claims 21 to 23, wherein the second moiety is a tag, a polypeptide, or a hapten. 【

25. An adapter molecule according to any one of claims 21 to 24, wherein the tag is selected from the group consisting of a His tag, a Myc tag, a cotinine tag, a FITC tag, a Biotin tag, a Leucin zipper tag, a Flag tag, an Xpress tag, an Avi tag, a calmodulin binding peptide (CBP) tag, a polyglutamate tag, an HA tag, a Strep tag, Softag 1, Softag 3, and a V5 tag.

26. An adapter molecule according to any one of claims 21 to 25, wherein the first moiety is an anti-CD3 antibody or an antigen-binding fragment thereof, and / or the second moiety is a His tag. 【

27. ​​An antibody according to any one of claims 21 to 26, wherein the first moiety comprises a light chain variable region comprising 0KT3, UCHT1, a CDR1 consisting of the amino acid sequence of SEQ ID NO: 23, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 24, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 25, and a heavy chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 26, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 27, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 28; An adapter molecule selected from the group consisting of an antibody comprising a light chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 32, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 33, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 34, and a heavy chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 35, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 36, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 37; and an antibody comprising a light chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 67, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 68, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 69, and a heavy chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 70, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 70, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 72, wherein the second moiety is a His tag.

Citation Information

Patent Citations

  • Companion animal autonomous walking drone

    KR1020220113557A

  • Method and Apparatus for releasing RRC connection based on RRC message in non-terrestrial network

    KR1020230090228A

  • Therapeutic molecules that bind to LAG3 and PD1

    WO2019158942A1

  • KR20220008841A